Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rani Therapeutics Holdings

0.4169
+0.00691.68%
Post-market: 0.4103-0.0066-1.58%19:57 EDT
Volume:1.68M
Turnover:712.54K
Market Cap:16.36M
PE:-0.42
High:0.4468
Open:0.4100
Low:0.4100
Close:0.4100
Loading ...

Rani Therapeutics Announces New Securities Purchase Agreement

TIPRANKS
·
Yesterday

Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views

Benzinga
·
16 Jul

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

GlobeNewswire
·
15 Jul

Rani Therapeutics Secures Reduced Warrant Exercise Price Deal with Institutional Investor

Reuters
·
11 Jul

Genelux Corporation Appoints Eric Groen as General Counsel and Head of Business Development

Reuters
·
07 Jul

Rani Therapeutics Holdings Inc. Implements Stockholder-Approved Actions to Expedite Decision-Making

Reuters
·
01 Jul

Rani Therapeutics Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Rule

Reuters
·
27 Jun

Rani Therapeutics Holdings Inc. Conducted Annual Stockholders Meeting

Reuters
·
30 May

Rani Therapeutics Secures $4.3M via Series D Warrant

TIPRANKS
·
20 May

Rani Therapeutics Holdings Inc. Announces Share Transactions: Issues Series D Warrant and Lowers Exercise Prices for Series B and C Warrants

Reuters
·
20 May

Rani Therapeutics Announces Research Agreement With Chugai

THOMSON REUTERS
·
19 May

Oppenheimer Adjusts Rani Therapeutics Price Target to $4 From $14, Maintains Outperform Rating

MT Newswires Live
·
16 May

BRIEF-Rani Therapeutics Q1 Net Income USD -12.738 Million

Reuters
·
14 May

Rani Therapeutics Hldgs Q1 EPS $(0.22) Misses $(0.21) Estimate, Sales $172.00K

Benzinga
·
14 May

Press Release: Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Dow Jones
·
14 May

Rani Therapeutics Faces Nasdaq Compliance Challenge

TIPRANKS
·
07 May

Rani Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

Rani Therapeutics Holdings: Buy Rating Backed by Strong Financial Position and Promising Clinical Trials

TIPRANKS
·
03 Apr

RANI: 2024 Financial Results

Zacks Small Cap Research
·
01 Apr

Stifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)

TIPRANKS
·
01 Apr